SelectQuote, Inc. (SLQT) is a technology-enabled, direct-to-consumer platform specializing in the distribution of insurance policies and healthcare services. The company connects consumers with insurance carrier partners through its proprietary technology and skilled agents, offering a range of insurance products and healthcare solutions. Its operations focus on maximizing customer lifetime value and improving health outcomes through innovative services.
- Senior - Offers Medicare-related products, including Medicare Advantage, Medicare Supplement, prescription drug plans, and ancillary products like dental, vision, and hearing coverage.
- Healthcare Services - Provides pharmacy services through SelectRx, including prescription medications, customized packaging, and medication therapy management to enhance health outcomes and medication adherence.
- Life - Distributes life insurance policies tailored to individual consumer needs.
- Auto & Home - Facilitates comparison shopping for automobile and home insurance policies.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Timothy R. Danker ExecutiveBoard | Chief Executive Officer | Timothy R. Danker has been the CEO of SelectQuote, Inc. since 2017 and has served on its Board of Directors since 2017. | View Report → | |
Daniel A. Boulware Executive | General Counsel and Secretary | Daniel A. Boulware has served as General Counsel and Secretary of SelectQuote, Inc. since October 2019, and previously served as Vice President and General Counsel at SS&C Health. He began his legal career at Polsinelli PC in 2002 and was promoted to Shareholder in 2012. | ||
Joshua B. Matthews Executive | President of SelectQuote's Senior Division | Joshua B. Matthews has served as President of SelectQuote's Senior Division since July 2022. He previously held executive roles including Executive Vice President of Medicare Sales Operations from July 2019 to June 2022 and joined SelectQuote in 2014. | ||
Robert Grant Executive | President of SelectQuote | Robert Grant has served as the President of SelectQuote since October 2021. Previously, he held several leadership roles at SLQT, including President of the Senior Division from 2019 to 2021 and Chief Revenue Officer from 2017 to 2019. | ||
Ryan M. Clement Executive | Chief Financial Officer | Ryan M. Clement is the Chief Financial Officer of SelectQuote, Inc. since February 2023, having previously served as Interim CFO from June 2022 and as Senior Vice President of Financial Planning & Analysis starting January 2022. | ||
Ryan Souan Executive | Chief Marketing Officer | Ryan Souan is the Chief Marketing Officer at SLQT since April 2024. Previously, he held various executive roles including EVP of Marketing and Vice President positions at SLQT from 2017 onwards. | ||
Sarah Anderson Executive | Executive Vice President of Pharmacy Services | Sarah Anderson has served as the Executive Vice President of Pharmacy Services at SLQT since July 2024, after holding several senior marketing and operational roles at the company, including as Senior Director of Marketing for the Senior division since 2018. She brings extensive expertise in healthcare services and corporate strategy from her varied roles. | ||
Stephanie Fisher Executive | Chief Accounting Officer | Stephanie Fisher serves as Chief Accounting Officer at SelectQuote, Inc. since August 2020; previously, she served as CFO at Yellow Corporation from 2017 to 2020. | ||
William Grant III Executive | Chief Operating Officer | William Grant III has served as Chief Operating Officer at SLQT since 2019, and previously served as Chief Marketing Officer and President of the Senior Division from 2017 to 2019, as well as Senior Vice President of Marketing for the Senior Division from 2012 to 2017. |
- Given that your tenured agent force delivered close rates 24% higher and drove a 33% increase in productivity with a 22% reduction in agent count, how will you recalibrate your agent force strategy in future AEP seasons to balance capital constraints with growth opportunities?
- With the recent $350 million preferred equity offering and delays in completing securitizations impacting your agent headcount, how do you plan to optimize capital deployment to ensure that you capture additional MA business in future cycles?
- Your revised fiscal 2025 guidance appears conservative relative to the quarter’s performance; can you clarify what specific market headwinds or operational uncertainties are justifying this cautious outlook and how you intend to bridge that gap?
- Considering the significant investments made in Select RX and its role in driving healthcare services profitability, what targeted improvements in technology and marketing are you planning to implement to enhance customer acquisition efficiency and margin expansion?
- With the new regulatory regime appearing more favorable, what concrete steps are you taking to mitigate risks associated with policy terminations and to leverage these changes for accelerated growth in your Medicare Advantage segment?
Research analysts who have asked questions during SelectQuote earnings calls.
George Sutton
Craig-Hallum
4 questions for SLQT
Patrick McCann
Noble Capital Markets
4 questions for SLQT
Ben Hendrix
RBC Capital Markets
2 questions for SLQT
Benjamin Hendrix
RBC Capital Markets
2 questions for SLQT
George Stottman
Craig-Hallum Capital Group LLC
1 question for SLQT
Matt McCann
NOBLE Capital Markets
1 question for SLQT
Michael Murray
RBC Capital Markets
1 question for SLQT
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The company identifies this competitor as one of its primary rivals in the distribution of insurance products through direct-to-consumer online platforms. | |
This competitor is noted as a primary rival in the insurance distribution market, leveraging online platforms to connect consumers with insurance products. | |
Accudose Pharmacy | In the pharmaceutical market, this competitor operates as a closed-door pharmacy, competing with SelectRx's services. |
ExactCare Pharmacy | This competitor is another closed-door pharmacy in the pharmaceutical market, competing with SelectRx's offerings. |
This traditional brick-and-mortar pharmacy primarily sells directly to customers in person, competing with SelectRx's services. | |
This competitor operates as a traditional brick-and-mortar pharmacy, selling directly to customers in person and competing with SelectRx. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
UHC | SLQT sells UHC’s insurance policies for commissions. | All | Revenue Share: 30% (FY 2024) , 33% (FY 2023) , 18% (FY 2022). |
Humana | SLQT sells Humana’s insurance policies for commissions. | All | Revenue Share: 17% (FY 2024) , 20% (FY 2023) , 12% (FY 2022). |
Aetna | SLQT sells Aetna’s insurance policies for commissions. | All | Revenue Share: 16% (FY 2024). |
WellCare | SLQT sells WellCare’s insurance policies for commissions. | All | Revenue Share: 17% (FY 2022). |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Chronic Care Management Platform (SPM) | 2024 | The deal was valued at $4.0 million—with $3.4 million in cash—resulting in $3.3 million of intangible assets (proprietary technology) and $0.3 million of goodwill, and it was executed to launch SelectPatient Management (SPM) to offer scalable, technology-enhanced chronic care services that improve patient engagement and support providers. |
Simple Meds | 2021 | SelectRx acquired Simple Meds for an aggregate purchase price of $7.0 million (adjusted to $7.408 million) to accelerate its prescription drug management operations, integrating assets such as customer relationships and expanding its licensing footprint from 11 to 47 states. |
Express Med Pharmaceuticals (rebranded as SelectRx) | 2021 | The acquisition was structured as up to a $24.0 million deal (comprising $17.5 million in cash, a $2.5 million holdback, and an earnout of up to $4.0 million) aimed at incorporating Express Med’s high-touch, technology-driven model into the Population Health platform, enhancing medication adherence and strategic partnerships while maintaining the existing leadership team. |
Recent press releases and 8-K filings for SLQT.
- Faruqi & Faruqi, LLP is investigating SelectQuote (SLQT) for alleged federal securities law violations, encouraging investors who purchased securities between September 9, 2020, and May 1, 2025, to contact them.
- A federal securities class action has been filed against SelectQuote, with a October 10, 2025 deadline for investors to seek the role of lead plaintiff.
- The complaint alleges SelectQuote directed Medicare beneficiaries to plans that best compensated the company, regardless of suitability, and received illegal kickbacks.
- On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint, alleging SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 through at least 2021.
- Following this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025.
- A class action lawsuit has been filed against SelectQuote, Inc. (SLQT) by Bragar Eagel & Squire, P.C., on behalf of investors who purchased or acquired the company's securities between September 9, 2020, and May 1, 2025.
- The lawsuit follows a U.S. Department of Justice (DOJ) complaint filed on May 1, 2025, alleging SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies from 2016 through at least 2021 for steering Medicare beneficiaries to certain plans.
- The DOJ concluded that SelectQuote made materially false claims by stating it offers "unbiased coverage comparisons" while allegedly directing beneficiaries to plans offered by insurers that paid them the most.
- On May 1, 2025, following the news of the DOJ complaint, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share.
- Investors have until October 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- SelectQuote (SLQT) is facing a securities class-action lawsuit, Pahlkotter v. SelectQuote Inc. et al., after the U.S. Department of Justice (DOJ) intervened in a whistleblower lawsuit alleging deceptive Medicare Advantage sales practices.
- The lawsuit, covering investors who purchased SelectQuote stock between September 9, 2020, and May 1, 2025, alleges the company misled the market about its business model and regulatory exposure.
- Core allegations include steering customers toward plans offering the highest commissions, accepting illegal kickbacks, and violating federal statutes, with the DOJ claiming improper payments and discrimination against less profitable customers from 2016 through at least 2021.
- The federal action led to a 19% drop in SelectQuote’s share price on May 1, 2025, and shares have declined more than 40% over the past six months due to investor concern.
- A class action lawsuit has been filed against SelectQuote, Inc. (NYSE:SLQT) on behalf of investors who purchased or acquired securities between September 9, 2020, and May 1, 2025.
- Investors have until October 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- The lawsuit stems from a U.S. Department of Justice (DOJ) False Claims Act complaint filed on May 1, 2025, which alleged SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies between 2016 and at least 2021.
- The DOJ claimed SelectQuote directed Medicare beneficiaries to plans offered by insurers that paid the most money, rather than providing unbiased coverage comparisons.
- Following this news on May 1, 2025, SelectQuote’s stock price fell $0.61, or 19.2%, to close at $2.56 per share.
- Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. (NYSE:SLQT) for alleged violations of federal securities laws.
- The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that best compensated the company, did not provide unbiased comparison shopping, and received illegal kickbacks.
- On May 1, 2025, the U.S. Department of Justice (DOJ) filed a False Claims Act complaint against SelectQuote, alleging "tens of millions of dollars" in "illegal kickbacks" from 2016 through at least 2021.
- Following the DOJ news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025.
- The deadline for investors who suffered losses between September 9, 2020, and May 1, 2025, to seek the role of lead plaintiff in the federal securities class action is October 10, 2025.
- SelectQuote Inc. (SLQT) is facing a securities class-action lawsuit after the U.S. Department of Justice (DOJ) intervened in a whistleblower lawsuit alleging deceptive sales practices.
- The lawsuit, Pahlkotter v. SelectQuote Inc. et al., covers investors who purchased stock between September 9, 2020, and May 1, 2025, with a lead plaintiff deadline of October 10, 2025.
- Allegations include SelectQuote steering customers towards plans with the highest commissions, accepting illegal kickbacks, and violating federal statutes, with the DOJ alleging tens of millions in improper payments from 2016 through at least 2021.
- SelectQuote's share price dropped 19% on May 1, 2025, following the DOJ's involvement, and has declined more than 40% over the past six months due to investor concerns.
- Kahn Swick & Foti, LLC (KSF) reminds investors of the October 10, 2025, deadline to file lead plaintiff applications in a securities class action lawsuit against SelectQuote, Inc. (SLQT).
- The lawsuit alleges that SelectQuote and certain executives failed to disclose material information during the Class Period from September 9, 2020, to May 1, 2025.
- The allegations are based on a May 1, 2025, U.S. Department of Justice (DOJ) False Claims Act complaint, which claims SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurers between 2016 and at least 2021 for steering Medicare beneficiaries to specific plans.
- Following the news of the DOJ complaint, SelectQuote's shares fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025.
- SelectQuote Inc. is facing a securities class-action lawsuit after the U.S. Department of Justice (DOJ) intervened in a whistleblower lawsuit alleging deceptive Medicare Advantage sales practices, including steering customers to higher-commission plans and accepting illegal kickbacks.
- The DOJ alleges SelectQuote received tens of millions of dollars in improper payments and discriminated against less profitable customers from 2016 through at least 2021.
- The federal action triggered a 19% drop in SelectQuote’s share price on May 1, 2025, and the class-action lawsuit covers investors who purchased stock between September 9, 2020, and May 1, 2025.
- The lead plaintiff deadline for the class-action lawsuit is October 10, 2025.
- A class action lawsuit has been filed against SelectQuote, Inc. (SLQT) on behalf of investors who purchased securities between September 9, 2020, and May 1, 2025.
- The lawsuit follows a U.S. Department of Justice (DOJ) False Claims Act complaint filed on May 1, 2025, alleging SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies from 2016 through at least 2021.
- The DOJ claims SelectQuote steered Medicare beneficiaries to plans that offered the highest compensation, rather than providing unbiased comparisons, and engaged in a conspiracy to discriminate against less profitable beneficiaries.
- Following the news of the DOJ complaint, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025.
- Investors have until October 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- SelectQuote Inc. (SLQT) is facing a securities class-action lawsuit, Pahlkotter v. SelectQuote Inc. et al., following the U.S. Department of Justice (DOJ) intervention in a whistleblower lawsuit alleging deceptive sales practices.
- The lawsuit claims SelectQuote misrepresented its Medicare Advantage sales practices, including steering customers towards plans with the highest commissions, accepting illegal kickbacks, and violating federal statutes like the False Claims Act.
- The DOJ's complaint alleges that from 2016 through at least 2021, SelectQuote received tens of millions of dollars in improper payments and discriminated against less profitable customers.
- The DOJ's involvement caused SelectQuote's share price to drop 19% on May 1, 2025, and over 40% in the past six months.
- The class-action lawsuit covers investors who purchased SelectQuote stock between September 9, 2020, and May 1, 2025, with a lead plaintiff deadline of October 10, 2025.